Top Markets
Coin of the day
Sigilon Therapeutics, Inc. Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

SGTX
Pozycja w akcjach #25418
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015,... Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
Cena akcji
$22.47
Ostatnia synchronizacja: 2023-08-18
Kapitalizacja rynkowa
$49.76M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Sigilon Therapeutics, Inc. (SGTX)

Kategoria

Historia ceny akcji dla Sigilon Therapeutics, Inc. (SGTX)
Najwyższa cena zamknięcia: $22.30 dnia 2023-08-01

Najniższa cena zamknięcia: $453.71 dnia 2020-12-01
Historia cen akcji firmy Sigilon Therapeutics, Inc. od 2020 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2023 400.06%
2022 -87.99%
2021 -91.82%
2020 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$539.14 35.65%
US
$1.04K 56.21%
NL
$117.80 -18.86%
AU
$761.87 8.65%
CH
$130.43 397.46%
US